1106 Fin Apollomics
BioCentury & Getty Images


Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

Ping An Capital leads series C round for cross-border cancer in-licensing play

Cross-border play Apollomics raises a series C led by Ping An Capital and backed by a broad syndicate of Asian investors to in-license and develop cancer therapeutics.

Nov 7, 2020 | 2:38 AM GMT


Read the full 684 word article

* The registration to this event is no longer available. To find out information about upcoming events, feel free to visit www.biocentury.com/conferences.